BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

• Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology
• Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient derived pancreatic cancer model
• No clinical and histopathologic signs of toxicities in non-human primates with conditionally active tetravalent B7-H3 x CD3 T-cell engager (BA3142)
  

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting to be held at the San Diego Convention Center in San Diego, California from April 5–10, 2024. 

Presentation Details:

Poster Title:		Using a novel NextGen linker system to generate a Conditionally Active Biologic (CAB) anti-Nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primates
Authors:		Jing Wang, Jian Chen, Gerhard Frey, Haizhen Liu, Charles Xing, Kathryn Woodard, Cathy Chang, William J. Boyle, and Jay M. Short
Poster Number:		743 / 29
Session:		PO.ET02.06 - Tumor Microenvironment
Date / Time:		Sunday, April 7, 2024 / 1:30 – 5:00 PM PT
Location:		Section 29

         

Poster Title:		Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid Tumors
Authors:		Ana Paula Cugnetti, Haizhen Liu, Patricia McNeeley, Charles Xing, Kathryn Woodard, Cathy Chang, Gerhard Frey, William J. Boyle, and Jay M. Short
Poster Number:		6340 / 1
Session:		PO.CL06.08 - Antibodies 2
Date / Time: